Brainstorm cell therapeutics to provide corporate update on phase 3b nurown® trial at the 2024 maxim healthcare virtual summit

New york , oct. 7, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq:bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 maxim healthcare virtual summit. chaim lebovits, president and ceo of brainstorm, will join jason mccarthy, ph.d.

BCLI Ratings Summary

BCLI Quant Ranking